A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

* Participant has provided written consent. * If female, participant is postmenopausal or surgically sterile. * If male, must be practicing two effective methods of birth control. * Participant is hepatitis C virus (HCV) genotype 1 with HCV ribonucleic acid levels \>50,000 IU/mL. * Participants must demonstrate chronic hepatitis C infection for at least 6 months prior to study enrollment. * Participants must have a liver biopsy with histology consistent with HCV-induced liver damage, and with no evidence of cirrhosis or liver pathology due to any cause other than chronic HCV. * Condition of general good health other then HCV infection. * Participants with a history of thyroid disease must have a thyroid stimulating hormone (TSH) value in the normal range.

* No prior history of receiving therapy for HCV infection. * Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg), or human immunodeficiency virus antibody (HIV Ab). * Pregnant or breastfeeding females or male partners of women who are pregnant. * History of seizures or cancer. * History of major depressive disorder within 2 years. * Any current or past history of cirrhosis. * Any cause of liver disease other than chronic HCV infection.